BUFFALO, N.Y. – University at Buffalo researchers have identified for the first time an enzyme in the foxglove plant that is responsible for the production of compounds needed to make the heart ...

Digoxin, a cardiac glycoside derived from the foxglove plant, has been a mainstay of treatment in systolic heart failure and in rate control for atrial fibrillation. By inhibiting the cardiac ...

University at Buffalo researchers have identified for the first time an enzyme in the foxglove plant that is responsible for the production of compounds needed to make the heart failure drug digoxin.

Foxglove, a flowering plant long feared for its toxicity, became an unlikely source of a widely studied heart drug. Digoxin, a cardiac glycoside associated in modern medicine with Digitalis species ...

A strong, rhythmic pulse is a lifelong companion for those with a healthy heart. But for about 1% of babies born in the U.S. every year, developmental heart problems compromise that steady beat. One ...

MADRID -- Digitoxin added to guideline-directed medical therapy improved outcomes among patients with heart failure and reduced ejection fraction (HFrEF), the DIGIT-HF trial showed. The cardiac ...

A low dose of digoxin ensures that people with heart failure are hospitalized and die less frequently. This emerges from three studies led by UMCG cardiologists Dirk Jan van Veldhuisen, Kevin Damman, ...

Faced with these conflicting results, doubts arose regarding the potential danger of the drug, and prescriptions for digoxin for hospitalized HF patients plummeted, particularly in the United States.

Cardiac glycosides derived from the foxglove plant have been used in cardiology for two centuries, but digoxin and digitoxin have gradually fallen out of favor and are now considered controversial in ...